GleamWall
中文EN

PTIX Protagenic Therapeutics, Inc.\new

Pharmaceutical Preparations · OTC · SEC CIK 1022899 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY168.9%
TTM EPS YoY138.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA155.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets50.8%
Debt / equity0.00x
Current ratio0.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.30x
Accruals ratio201.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-09-302026Q12026-06-302026Q4*2026-03-312026Q3*2025-12-312026Q2*2025-09-302026Q12025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue——$0$0$0$0$0$0
R&D expense$26,904$109,925$80,769$153,786$218,343$394,112$880,372$134,580
SG&A expense$64,491$97,980-$157,555$154,817$108,933$50,089$567,736$49,697
Operating income-$670,601-$961,247-$120,331-$925,103-$1.11M-$1.21M-$1.45M-$401,401
Pretax income-$667,194-$963,616$5.08M$2.21M-$869,496-$5.06M-$1.44M-$850,287
Net income-$667,194-$963,616$5.08M$2.21M-$869,496-$5.06M-$1.44M-$850,287
EBITDA-$667,690-$952,935-$108,830-$912,531-$1.10M-$1.20M-$1.44M-$401,401
EPS (basic)-0.37-0.53—1.14-0.47-1.37-2.75-0.16
EPS (diluted)-0.37-0.53—1.14-0.47-1.37-2.75-0.16
Weighted avg. shares (diluted)1.81M1.81M—1.93M1.85M3.70M523,1855.40M
Banking
Net interest income$3,407$10,763-$1.31M$23,831$34,337-$238,727-$351,740-$448,886
Balance sheet
Cash & equivalents$76,909$565,985$1.51M$2.21M$2.72M$4.10M$14,531$79,568
Inventory———$1,074$1,075$1,095$1,038—
Current assets$188,464$709,871$1.54M$2.30M$2.86M$4.33M$89,093$1.88M
PP&E, net$3,333$6,244$14,556$38,836$51,407$63,979$60,474$73,046
Intangibles$2.08M$2.08M$2.09M$2.09M$2.09M$2.09M——
Total assets$2.27M$2.80M$3.65M$4.43M$5.00M$6.49M$89,093$1.96M
Current liabilities$1.15M$1.07M$1.03M$6.82M$9.70M$10.46M$5.04M$942,759
Total liabilities$1.15M$1.07M$1.03M$6.82M$9.70M$10.46M$5.04M$942,759
Shareholders' equity$1.12M$1.72M$2.62M-$2.39M-$4.70M-$3.97M-$4.95M-$3.32M
Shares outstanding1.81M1.81M1.81M1.93M1.93M1.85M5.80M517,257
Cash flow statement
Operating cash flow-$488,889-$944,298$265,533-$509,667-$1.40M-$1.75M-$1.07M-$353,640
Investing cash flow——-$313,297$0$0$943,180—-$1.22M
Financing cash flow——-$533,898-$2-$15,405$5.01M$102,519$1.37M
Depreciation & amortization$2,911$8,312$11,501$12,572$12,572$12,571$12,572$0
Stock-based compensation$62,409$67,012$91,652$95,942$105,868$125,127$236,014$245,436

Free plan shows the latest 8 periods; Pro shows all 57 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.